(Q34380366)

1 August 2017

title

Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast (English)

1 reference

1 August 2017

1 reference

1 reference

8

Funda Meric-Bernstam

1 reference

1 August 2017

9

Kelly K Hunt

1 reference

1 August 2017

2

Aman U Buzdar

1 reference

1 August 2017

Henry M Kuerer

1

1 reference

1 August 2017

Elizabeth A Mittendorf

3

1 reference

1 August 2017

Francisco J Esteva

4

1 reference

1 August 2017

Anthony Lucci

5

1 reference

1 August 2017

Luis M Vence

6

1 reference

1 August 2017

Laszlo Radvanyi

7

1 reference

1 August 2017

William Fraser Symmans

10

1 reference

1 August 2017

language of work or name

English

0 references

publication date

24 August 2010

1 reference

1 August 2017

1 reference

1 August 2017

volume

117

1 reference

1 August 2017

issue

1

1 reference

1 August 2017

page(s)

39-47

1 reference

Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer

1 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2997136

HER-2/neu overexpression as a predictor for the transition from in situ to invasive breast cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2997136

Development and validation of cell-based ELISA for the quantification of trastuzumab in human plasma.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2997136

Ductal carcinoma in situ: state of the science and roadmap to advance the field

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2997136

Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2997136

Neoadjuvant trastuzumab induces apoptosis in primary breast cancers

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2997136

The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2997136

HER-2/neu-derived peptide 884-899 is expressed by human breast, colorectal and pancreatic adenocarcinomas and is recognized by in-vitro-induced specific CD4(+) T cell clones

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2997136

Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2997136

Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2997136

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2997136

Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial.

6 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FCNCR.25399

Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FCNCR.25399

Tumour biology: herceptin acts as an anti-angiogenic cocktail.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FCNCR.25399

Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles

21 January 2018

1 reference

12 December 2020

Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: A guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ

1 reference

12 December 2020

Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy

1 reference

12 December 2020

Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines

1 reference

12 December 2020

High and differential expression of HER-2/neu extracellular domain in bilateral ductal fluids from women with unilateral invasive breast cancer

1 reference

12 December 2020

Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2

1 reference

12 December 2020

Identifiers

DOI

10.1002/CNCR.25399

1 reference

1 August 2017

1 reference

1 August 2017

1 reference